- Home
- HMST vs BMEA Comparison
HMST vs BMEA Comparison
Compare HMST & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HMST
- BMEA
- Stock Information
- Founded
- HMST 1921
- BMEA 2017
- Country
- HMST United States
- BMEA United States
- Employees
- HMST N/A
- BMEA N/A
- Industry
- HMST Major Banks
- BMEA Biotechnology: Pharmaceutical Preparations
- Sector
- HMST Finance
- BMEA Health Care
- Exchange
- HMST Nasdaq
- BMEA Nasdaq
- Market Cap
- HMST 215.4M
- BMEA 145.0M
- IPO Year
- HMST 2012
- BMEA 2021
- Fundamental
- Price
- HMST $11.13
- BMEA $3.69
- Analyst Decision
- HMST Buy
- BMEA Buy
- Analyst Count
- HMST 2
- BMEA 13
- Target Price
- HMST $14.75
- BMEA $37.25
- AVG Volume (30 Days)
- HMST 179.9K
- BMEA 1.1M
- Earning Date
- HMST 01-27-2025
- BMEA 10-29-2024
- Dividend Yield
- HMST N/A
- BMEA N/A
- EPS Growth
- HMST N/A
- BMEA N/A
- EPS
- HMST N/A
- BMEA N/A
- Revenue
- HMST $169,710,000.00
- BMEA N/A
- Revenue This Year
- HMST N/A
- BMEA N/A
- Revenue Next Year
- HMST $12.08
- BMEA N/A
- P/E Ratio
- HMST N/A
- BMEA N/A
- Revenue Growth
- HMST N/A
- BMEA N/A
- 52 Week Low
- HMST $8.09
- BMEA $3.61
- 52 Week High
- HMST $16.10
- BMEA $20.21
- Technical
- Relative Strength Index (RSI)
- HMST 45.21
- BMEA 23.76
- Support Level
- HMST $10.87
- BMEA $3.74
- Resistance Level
- HMST $12.14
- BMEA $4.30
- Average True Range (ATR)
- HMST 0.61
- BMEA 0.41
- MACD
- HMST 0.04
- BMEA 0.00
- Stochastic Oscillator
- HMST 36.88
- BMEA 1.88
About HMST HomeStreet Inc.
HomeStreet Inc is a commercial bank. It provides commercial loans and consumer loans including mortgage loans, deposit products, private banking, and cash management services. The company loan products include commercial business loans and agriculture loans, consumer loans, single family residential mortgages, loans secured by commercial real estate and construction loans for residential and commercial real estate projects.
About BMEA Biomea Fusion Inc.
Biomea Fusion Inc is a preclinical-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of irreversible small molecule drugs to treat patients with genetically defined cancers. The company's product candidate, BMF-219, is designed to be an orally bioavailable, potent and selective irreversible inhibitor of menin, an important transcriptional regulator known to play a direct role in oncogenic signaling in multiple cancers.